Carol Zhao

Efficacy and Safety of Palopegteriparatide Treatment in Adults With Hypoparathyroidism: 3-Year Results From the Phase 3 PaTHway Trial

Aliya Khan, B.L. Clarke, Mishaela R. Rubin, Michael S. Ominsky et autres

ca, us, dk, it, de (code pays fourni par la source)

Long-Term Efficacy and Safety of Palopegteriparatide Treatment in Adults With Chronic Hypoparathyroidism: 4-Year Results From the Phase 2 PaTH Forward Trial

Aliya Khan, Andrea Palermo, Mishaela R. Rubin, Peter E. H. Schwarz et autres

ca, us, dk, it, de (code pays fourni par la source)

Long-term efficacy and safety of palopegteriparatide treatment in adults with chronic hypoparathyroidism: 4-year results from the phase 2 path forward trial

Andrea Palermo, Aliya Khan, Mishaela R. Rubin, Peter E. H. Schwarz et autres

Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results

Aristides K Maniatis, Paul Thornton, Ulhas M. Nadgir, Elpis Vlachopapadopoulou et autres

Introduction: This international, Phase 3, open-label extension trial evaluated the long-term safety and efficacy of once-weekly lonapegsomatropin in children with growth hormone deficiency (GHD). METHODS: Conducted across 63 sites (15 countries), the enliGHten trial enrolled children with GHD who previously participated in …

us, gr, ru, am, pl, dk, nz (code pays fourni par la source)

Long-Acting Growth Hormone for Pediatric Growth Hormone Deficiency

Norbert Albers, Sarah Cadarette, Benjamin G. Feakins, María Arregui et autres

Long-acting growth hormone (LAGH) has the potential to improve adherence and outcomes over daily somatropin in growth hormone deficiency (GHD). Whereas daily somatropin products are molecularly identical, LAGHs are molecularly distinct; additional moieties or mechanisms that prolong LAGH action confer unique pharmacodynamic/pharmacokinetic …

de, us, gb, dk (code pays fourni par la source)

Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension

Richard N. Channick, Sarah Medrek, Marion Delcroix, Seán Gaine et autres

BACKGROUND Age affects disease severity and patient outcomes in pulmonary arterial hypertension. This post-hoc analysis identified prognostic age groups and associated macitentan/selexipag treatment effects. METHODS Randomized trials evaluated macitentan (SERAPHIN; NCT00660179) and selexipag (GRIPHON; NCT01106014) versus placebo (primary endpoint: time to morbidity/mortality …

us, ie, cz, at, ca, my, in, br, pl, it, fr (code pays fourni par la source)

7933 Baseline Demographics and Design of the SkybriGHt Registry Study. A US Multi-center, Prospective, Non-interventional, Long-term, Effectiveness and Safety Study of Children and Adolescents with Growth Hormone Deficiency Treated with Lonapegsomatropin

Philippe Backeljauw, Aristides K Maniatis, M. Jennifer Abuzzahab, Steven D. Chernausek et autres

Abstract Disclosure: P.F. Backeljauw: Advisory Board Member; Self; Ascendis Pharma, Inc., Novo Nordisk, BioMarin. Consulting Fee; Self; Ascendis Pharma, Inc., Novo Nordisk, BioMarin, Cavalry, Upsher-Smith. Speaker; Self; Ascendis Pharma, Inc., BioMarin. A.K. Maniatis: Advisory Board Member; Self; Alexion Pharmaceuticals, Inc., Ascendis Pharma, …

us (code pays fourni par la source)

SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation

Robert P. Frantz, Shashank Desai, Gregory A. Ewald, Verónica Franco et autres

Abstract Macitentan is a dual endothelin receptor antagonist (ERA) approved for treating pulmonary arterial hypertension (PAH). SOPRANO evaluated the efficacy and safety of macitentan versus placebo in pulmonary hypertension (PH) patients after left ventricular assist device (LVAD) implantation. SOPRANO was a phase …

us (code pays fourni par la source)

THU173 Subanalysis By Tanner Stage In Phase 3 Trials In Children And Adolescents With Growth Hormone Deficiency Treated With Lonapegsomatropin

Paul L. Hofman, Paul Thornton, Ulhas Nadgir, Paul Saenger et autres

Abstract Disclosure: P. Hofman: Speaker; Self; Novo Nordisk, Eli Lilly & Company. P.S. Thornton: Research Investigator; Self; Ascendis, Pfizer, Inc., Opko, Zealand, Rezolute, Spruce. Other; Self; Johnson &Johnson, Rezolute. U.M. Nadgir: None. P. Saenger: None. E. Chertok: None. E.M. Aghajanova: Speaker; Self; …

nz, us, ru, am (code pays fourni par la source)

Derivation of a Risk Score (REVEAL-ECHO) Based on Echocardiographic Parameters of Patients With Pulmonary Arterial Hypertension

Karim El‐Kersh, Carol Zhao, Gregory Elliott, Harrison W. Farber et autres

us (code pays fourni par la source)

Smoking history and pulmonary arterial hypertension: Demographics, onset, and outcomes

Adaani Frost, Carol Zhao, Harrison W. Farber, Raymond L. Benza et autres

us (code pays fourni par la source)

CLINICAL CHARACTERISTICS OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION AND TREATMENT PATTERNS: A REAL-WORLD ANALYSIS FROM SPHERE (SELEXIPAG: THE USERS DRUG REGISTRY)

Vallerie V. McLaughlin, Kelly Chin, Harrison W. Farber, Murali M. Chakinala et autres